Objective-Microparticles of iron oxide (MPIO) distort magnetic field creating marked contrast effects far exceeding their physical size. We hypothesized that antibody-conjugated MPIO would enable magnetic resonance imaging (MRI) of endothelial cell adhesion molecules in mouse atherosclerosis. Methods and Results-MPIO (4.5 m) were conjugated to monoclonal antibodies against vascular cell adhesion molecule-1 (VCAM-MPIO) or P-selectin (P-selectin-MPIO). In vitro, VCAM-MPIO bound, in dose-dependent manner, to tumor necrosis factor (TNF)-␣ stimulated sEND-1 endothelial cells, as quantified by light microscopy (R 2 ϭ0.94, Pϭ0.03) and by MRI (R 2 ϭ0.98, Pϭ0.01). VCAM-MPIO binding was blocked by preincubation with soluble VCAM-1. To mimic leukocyte binding, MPIO targeting both VCAM-1 and P-selectin were administered in apolipoprotein E Ϫ/Ϫ mice. By light microscopy, dual-targeted MPIO binding to endothelium overlying aortic root atherosclerosis was 5-to 7-fold more than P-selectin-MPIO (PϽ0.05) or VCAM-MPIO (PϽ0.01) alone. Dual-targeted MPIO, injected intravenously in vivo bound aortic root endothelium and were quantifiable by MRI ex vivo (3.5-fold increase versus control; PϽ0.01). MPIO were well-tolerated in vivo, with sequestration in the spleen after 24 hours.
M agnetic resonance imaging (MRI) has demonstrated substantial utility in phenotyping vascular disease. Using inherent physico-chemical properties that confer particular tissue relaxivities, it has been possible to characterize the vessel wall in atherosclerosis at a submillimeter level. 1, 2 However, to capitalize fully on the diagnostic potential of MRI requires imaging at molecular and cellular levels. [3] [4] [5] [6] [7] [8] [9] To achieve this, purpose-built contrast agents are needed that can identify molecules of interest with high specificity, while conveying sufficient contrast to be easily distinguished from unenhanced tissue.
Specificity can be achieved through conjugation of contrast agent with monoclonal antibodies or their immunospecific fragments F(ab), peptides, or peptide-mimetics. Previous approaches have included integrin-conjugated gadolinium-rich perfluorocarbon nanoparticles, 10 peptide-conjugated nanoparticles of iron oxide, 11 and fibrin-specific cyclic peptide labeled with gadolinium. 12 Gadolinium-based contrast agents shorten T1 providing positive contrast on T1-weighted images. However, for the quantities that can be delivered to an endothelial monolayer, the contrast effects are relatively modest. By comparison, iron oxide nanoparticles provide greater contrast effects, but require many particles to be delivered to a given voxel. Another potential drawback is that contrast effects are manifest in T 2 *-weighted images as dark signal areas that can be difficult to distinguish from surrounding tissue.
Recently, larger microparticles of iron oxide (MPIO) have been used for cellular imaging and tracking. 13, 14 For some applications the size of these particles would preclude delivery to the site of interest. However, for imaging endovascular targets, MPIO possess several positive attributes. Firstly, MPIO convey a payload of iron that is orders of magnitude greater than ultrasmall particles of iron oxide (USPIO). Secondly, the effects of MPIO on local magnetic field homogeneity, and therefore detectable contrast, extend a distance at least 50 times their physical diameter. 13 Thirdly, once bound to endothelium, MPIO remain intravascular thereby allowing bound MPIO to be readily distinguished from the vessel wall. Finally, conjugated MPIO may offer a generic tool for imaging endothelial-specific markers across a range of vascular pathologies such as inflammation, atherosclerosis, and angiogenesis.
In animal models of atherosclerosis, vascular cell adhesion molecule-1 (VCAM-1; CD106) mediates adhesion, rolling, and tethering of mononuclear leukocytes and facilitates their transmigration to the developing atherosclerotic plaque. [15] [16] [17] VCAM-1 expression is not constitutive, but is present at atherosclerosis-prone sites, even before macroscopic disease is apparent, with persistent expression in more advanced lesions. 16, 18 VCAM-1 is therefore a potentially useful marker for atherosclerosis from early stages. However, in vivo molecular imaging of the vascular endothelium presents particular challenges since the contrast agent has to bind in sufficient density to the target, a two-dimensional monolayer, that is exposed to significant physiological sheer stresses. The dynamics of leukocyte:endothelial binding are also complex and dependent on multiple receptor-ligand interactions. Initial leukocyte rolling is selectin-mediated, whereas firm adhesion is mediated by integrin binding to intercellular adhesion molecule-1 (ICAM-1) and VCAM-1, with the latter more important in initiation of atherosclerosis. "Adhesion dynamic modeling" predicts synergistic roles for selectins and integrins with transition between rolling and firm adhesion dependent on binding affinities and relative concentrations of receptor-ligand interactions. 19, 20 Accordingly, we adopted a dual antibody-conjugated MPIO approach for targeted MRI and applied this to the detection of adhesion molecules on the arterial endothelium of apolipoprotein E-knockout (apoE Ϫ/Ϫ ) mice.
Materials and Methods

Antibody Conjugation to Iron Oxide Microparticles
MPIO (4.5 m diameter) with p-toluenesulphonyl (tosyl) reactive surface groups (Invitrogen) were used for antibody conjugation. These tosyl groups react covalently with primary amino and sulfydryl groups predominantly in the Fc-region of antibodies, favoring optimal orientation. Purified monoclonal rat anti-mouse antibodies for VCAM-1 (clone M/K2) (Cambridge Bioscience Ltd), P-selectin (clone RB40.34), (Fitzgerald Industries Intl), or IgG-1 (clone Lo-DNP-1; Serotec) were covalently conjugated to MPIO, by incubation at 37°C for 20 hours, with constant rotation (1ϫ10 7 MPIO per 5 g antibody). Dual-targeted MPIO, incubated with VCAM-1 and P-selectin antibodies (2.5 g of each), were prepared in the same way.
MPIO were then washed twice in phosphate buffered saline (PBS) containing 0.1% bovine serum albumin (BSA) at 4°C and incubated with tris buffer (0.1 mol/L, 0.1% BSA, pH 7.4) for 4 hours at 37°C, to block remaining active tosyl sites. MPIO were rinsed in PBS (0.1% BSA) at 4°C for 5 minutes and stored at 4ϫ10 8 MPIO per mL PBS (0.1% BSA) at 4°C.
In Vitro Binding of Anti-VCAM-1-MPIO to TNF-␣-Stimulated sEND-1 Cells
Cells of a murine endothelial line (sEND-1) were cultured in Dulbecco Modified Eagle medium (Invitrogen) supplemented with 10% fetal bovine serum, 2 mmol/L L-glutamine, and 100 U/mL penicillin and 0.1 mg/mL streptomycin. Cells (8ϫ10 5 per 35 mm well) were incubated with 0.1, 1, 10, or 50 ng/mL murine recombinant TNF-␣ (R&D systems) for 20 hours at 37°C to induce endothelial VCAM-1 expression. Stimulated cells were incubated in duplicate with VCAM-MPIO or control IgG-1-MPIO (1.2ϫ10 6 per 2 mL media) for 30 minutes at RT, with constant mixing. Unbound MPIO were removed by extensive washing with PBS.
MPIO binding to cells was assessed in 4 fields of view per TNF-␣ dose by light microscopy (Leica DM R; ϫ20 objective) and quantified using ImagePro plus (Media Cybernetics).
MRI of Cell Phantoms
Resuspended sEND-1 cells were embedded in 2% high grade agarose. MRI was performed using an 11.7 Tesla vertical magnet (Bruker) and 40-mm probe. A 3D gradient echo sequence was used (TR/TEϭ4/90 ms, field of view [FOV] 30ϫ30ϫ30 mm, matrix size [512], 3 
ApoE ؊/؊ Mice
Homozygous apoE Ϫ/Ϫ mice, bred in a pathogen-free room, with constant temperature and humidity, were weaned at 3 weeks of age and transferred to Western diet (21% milk fat, 0.15% cholesterol: 100244 Dyets Inc) for 25 weeks. Experiments were performed according to UK Scientific Procedures Act (1986).
Left Ventricular Injection of MPIO
ApoE Ϫ/Ϫ mice were terminally anesthetized by isofluorane inhalation. The chest cavity was exposed and while the heart was beating, mice were injected via the left ventricle with P-selectin-MPIO (nϭ4 mice), VCAM-MPIO (nϭ7 mice), control IgG-1-MPIO (nϭ3 mice), or dual-ligand MPIO targeting P-selectin and VCAM-1 (nϭ6 mice) (1.2ϫ10 7 MPIO in 100 L PBS; Ϸ6 mg iron/kg body weight). After 5 minutes, the arterial tree was perfusion fixed via the left ventricle with 10 mL paraformaldehyde (4% in PBS).
In Vivo Systemic Administration of Dual-Targeted MPIO
ApoE Ϫ/Ϫ mice were anesthetized with Hypnorm (25 mg/kg, Bayer) and Hypnoval (25 mg/kg, Bayer) combined, administered subcutaneously. Dual-targeted MPIO or control IgG-1-MPIO (6ϫ10 7 MPIO/ 150 L PBS; Ϸ30 mg iron per kg body weight) were injected in vivo via the jugular vein (nϭ4 mice per group) and allowed to circulate for 30 minutes. Mice were terminally anesthetized and the arterial tree perfusion fixed via the left ventricle with 4% PFA, removed en bloc and embedded in a glass MR tube containing 2% agarose. 21 The heart was instilled with 4% PFA containing 2 mmol/L gadoteridiol (Prohance, Bracco) via the left ventricle and the tube sealed with 2% agarose containing 2 mmol/L gadoteridiol.
MRI Analysis
High resolution MRI of the arterial tree was performed ex vivo at 11.7 T using a 13 mm 1 H birdcage radiofrequency coil (RAPID Biomedical). A 3D gradient echo sequence was used (TEϭ4 ms/ TRϭ90 ms, FOV 13ϫ13ϫ19.5 mm, matrix size 256ϫ256ϫ384, two averages, imaging time Ϸ7 hours) with final resolution of 25ϫ25ϫ25 m after data reconstruction. Segmentation of bound MPIO was performed by an observer blinded to the MR image identities. MPIO binding was defined as a discrete circular low signal area on the luminal surface of aortic root in Ն2 consecutive MR images. MPIO appearing in multiple consecutive images were counted only once. Segmented images were 3D reconstructed using the 3D Constructor plug-in for ImagePro Plus to visualize MPIO contrast throughout the aortic root.
Statistical Methods
Data are meanϮSD. Quantification of cell-bound MPIO assessed by MRI and light microscopy were related to the dose of TNF-␣ using simple linear regression (GraphPad Prism 4, GraphPad Software Inc). Parametric data were compared using Student t tests, with statistical significance attributed at probability values Ͻ0.05.
Competitive Inhibition of VCAM-MPIO Binding In Vitro
Please see supplementary methods, available online at http://atvb.ahajournals.org.
Assessment of In Vitro Macrophage and sEND-1 Cell Uptake of MPIO by MRI
Please see supplementary methods.
Histology
Assessment of MPIO Uptake by Organs Following In Vivo Administration
Results
VCAM-MPIO Bind to TNF-␣-Stimulated sEND-1 Cells
Assessed by light microscopy, VCAM-MPIO bound to TNF-␣-stimulated sEND-1 cells, but did not bind to unstimulated cells. IgG-1-MPIO did not bind to TNF-␣-stimulated sEND-1 cells. The number of cell-bound VCAM-MPIO increased with increasing doses of TNF-␣ ( Figure 1A , R 2 ϭ0.94, Pϭ0.03). High-resolution MRI of cell phantoms showed punctate low signal areas representing VCAM-MPIO binding to cells, which increased in a similar fashion to increasing dose of TNF-␣ ( Figure 1B 
Assessment of MPIO Uptake by Macrophages and sEND-1 Cells
Mouse peritoneal macrophages and sEND-1 cells were incubated with unconjugated MPIO in vitro. By light microscopy, macrophages phagocytosed MPIO after 30 minutes, and more so by 2 hours. By contrast, there was no MPIO uptake by sEND-1 cells ( Figure 2C ). With high resolution MRI, discrete low signal circular areas were observed for macrophage cell phantoms preincubated with MPIO for 30 minutes which increased further by 2 hours (Pϭ0.004; Figure 2 ). The equivalent quantification for sEND-1 cells incubated with MPIO for 30 minutes or 2 hours showed no difference from sEND-1 cells alone, indicating absence of uptake.
Single Versus Dual-Targeted MPIO Binding in Mouse Atherosclerosis
VCAM-MPIO and P-selectin-MPIO bound specifically to endothelium overlying atherosclerotic plaque after left ventricular injection in terminally anesthetized mice. The number of VCAM-MPIO and P-selectin-MPIO bound per aortic root section was similar (16.1Ϯ2.7 versus 12.9Ϯ4.2) with minimal nonspecific retention of IgG-1-MPIO (1.7Ϯ4.2; Figure  3 ). Dual-targeted MPIO showed significantly enhanced binding efficiency compared with P-selectin-MPIO (6.9 fold increase; Pϭ0.027) and VCAM-MPIO (5.5 fold increase; Pϭ0.005). 
In Vivo Dual-Targeted MPIO Binding to Atherosclerosis: Quantification With Ex Vivo MRI
Dual-targeted MPIO or IgG-1-MPIO were injected in vivo via the jugular vein and allowed to circulate for 30 minutes. High-resolution ex vivo MRI detected discrete circular low signal areas on the luminal side of the aortic root, in areas overlying atherosclerotic plaques. The contrast effect extended over Ϸ8 voxels. The appearance of MPIO changed in a consistent and characteristic fashion, and varied according to their position within a voxel ( Figure 4A ). The number of dual-targeted MPIO binding, determined by MRI, was 3.5fold higher compared with IgG-1-MPIO (14Ϯ4.2 versus 4Ϯ1.8; PϽ0.01; Figure 4B ). 3D reconstruction of segmented images demonstrated that MPIO binding was localized to atherosclerotic plaque endothelium throughout the aortic root. No MPIO binding was observed in atherosclerosis-free areas of the ascending aorta ( Figure 4C ).
Histological Assessment of Organs After In Vivo MPIO Administration
All mice tolerated MPIO injection and none showed signs of ill health up to 24 hours postinjection. MPIO were identified in lungs, kidneys, liver, and spleen after 30 minutes and 24 hours. Importantly, there was no evidence of infarction, hemorrhage, edema, inflammation, or MPIO extravasation in any of these organs, at either time point. Compared with 30 minutes, at 24 hours postinjection there was significant clearance of MPIO from the lungs (78% decrease; PϽ0.001) and kidneys (65% decrease; PϽ0.001) with redistribution of MPIO predominantly to the spleen (305% increase; PϽ0.001) and to a lesser extent, the liver (69% increase; PϽ0.01; Figure 5 ).
Discussion
The activated endothelium displays numerous molecules upregulated in vascular disease providing potential markers for functional molecular imaging and targeted therapeutics. An important challenge for in vivo molecular imaging is to deliver a potent contrast agent in sufficient quantity under conditions of shear stress. Here we combine intense MR contrast effects attainable using microparticles of iron oxide with a dual ligand-targeting strategy modeled on leukocyte interactions with activated endothelium.
Recently, MPIO have been used for imaging inflammatory cells in transplant rejection 14 and for tracking single cells during embryogenesis. 13 The accessibility of the endothelium to intravascular contrast agents permits the use of MPIO that are orders of magnitude larger than USPIO used previously for similar applications. We report the use of targeted MPIO that specifically bind to adhesion molecules in mouse athero- sclerosis after in vivo administration and which are readily identified by ex vivo MRI.
Dual antibody-conjugated MPIO, targeting both P-selectin and VCAM-1, were developed to mimic in vivo dynamics of leukocyte binding to endothelium. Initial leukocyte rolling, which is selectin-mediated, can be simulated under flow conditions using colloidal microspheres coated with sialyl Lewis x or P-selectin glycoprotein ligand-1. 22 Firm adhesion is mediated by integrin binding to ICAM-1 and VCAM-1. As predicted by computed models, dual-targeted MPIO showed synergistically enhanced binding compared with either in isolation. A similar approach targeting ultrasound microbubbles to vascular endothelium used a combination of sialyl Lewis x and ICAM-1 antibody, though binding efficiency was increased only marginally, possibly because of stearic limitation from size mismatch between the 2 ligands. 23 The role of VCAM-1 in the pathogenesis of atherosclerosis is well established in animal models, where it has been shown to be important in monocyte recruitment. 15, 18 In humans, Davies et al found VCAM-1 expression in a majority of human coronary atherosclerotic plaques post mortem 24 though this is not always consistent. 25 High resolution ex vivo MRI showed that, after intravenous injection, dual-targeted MPIO localized rapidly and specifically to aortic root plaque endothelium, a characteristic site for atherosclerosis development in mice. Although MPIO binding was not confluent, the "bloom effect" of magnetic field distortion of MPIO was clearly identifiable as circular low signal areas within the vessel lumen. We did not observe binding to atherosclerosis-free segments of the ascending aorta. Earlier approaches to endothelial molecular MRI have been limited by a lack of sensitivity. 26, 27 To address this, Nahrendorf et al recently used phage display to generate a specific VCAM-1 ligand that is internalized allowing progressive concentration by endothelial cells. By tagging this ligand with iron it was possible to image VCAM-1 expression in mouse atherosclerosis. 28 This is an ingenious approach, but, in comparison to MPIO, also has significant disadvantages. Firstly, cellular uptake is required, with potential for toxicity and ultimately loss of molecular specificity; secondly it was necessary to wait 48 hours after administration before imaging and thirdly, the mode of cellular uptake is so specific to VCAM-1 that the technology is not adaptable to other endovascular molecular targets.
The MPIO reported here are commercially available and can readily be substituted with other ligands of interest. We are currently exploring endogenous receptor ligands and novel peptides as mediators of MPIO binding. Technologies such as phage display can also facilitate identification of novel targets. 29 We have purposely used relatively large MPIO (4.5 m) because of their superiority as contrast vehicles. However, the conjugation technique can also be applied to smaller MPIO. The potential of MPIO for in vivo molecular imaging should also be emphasized. In this respect, Shapiro et al show excellent contrast using 1.63 m MPIO for cellular imaging, 13 whereas 1 m MPIO, which were cleared rapidly from the blood phase, have been used to monitor graft rejection. 14 The MPIO reported here are nonbiodegradeable and not suitable for human use. However, the basic iron contrast mechanism is potentially transferable to humans with suitable adaptation of the carriage particle. For example, biodegradable polymeric microparticles have been used as a vehicle for gadolinium-based contrast in MRI. 30 Indeed, clinical grade biodegradable iron-dextran particles are already available for injection into humans (eg, CliniMACS System, Miltenyi Biotec). The saturation magnetization of iron occurs at field strength of Ϸ2.1 T and would not be expected to increase at the higher field strengths used here. 31 For molecular imaging, the contrast effect should increase as the radius of the particle increases, to the third power. The contrast effects observed by us and others are in the region of 100 to 200 m per particle. Although the case is not proven here, this is of an order that may be detectable clinically.
Conclusions
We have shown that dual-ligand MPIO can be used for functional MRI of endothelial adhesion molecules in mouse atherosclerosis. We have exploited the opportunity of endovascular accessibility to use MPIO of similar size to circulating red blood cells (orders of magnitude larger than USPIO) that convey substantial contrast payload. To optimize MPIO binding under flow conditions in vivo, we have learnt from studies of leukocyte adhesion and computed models of dual-receptor binding to develop MPIO that target both P-selectin and VCAM-1. This work contributes an additional approach to the goal of disease characterization using functional molecular MRI probes.
